



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

Date:-14th September, 2018

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E)
Mumbai - 400 051
Scrip Code:ALPA

Dear Sir/Madam,

Sub: Clarifications for September, 2017 quarter results.

This has with reference to your letter, Please find quarterly results in the correct format and be noted that company has operated in a **SINGLE SEGMENT**, and the same has already been disclosed in the foot note of results.

Please find the enclosed documents.

Thanks and Regards.

For ALPA LABORATORIES LIMITED

Mahendra
MS CHAWLA
DIRECTOR
DIN :00362058

Enclosure: 1. Quarterly Results



Financial Results for Quarter ended 30th
September 2017

(Rs. in lacs, unless otherwise stated)

Particulars	Standalone Results					
	Quarter Ended			Six Month Ended		Year Ended
	Sep-17	Jun-17	Sep-16	Sep-17	Sep-16	Mar-17
	Unaudited					Audited
1. Income						
a) Revenue from operations	1558.76	1097.82	1274.86	2678.16	2853.22	6743.90
b) Other Income	114.28	149.01	145.34	263.38	324.00	671.66
Total income	1673.04	1246.83	1420.20	2941.54	3177.22	7415.56
2. Expenses						
a) Cost of materials consumed	846.24	766.78	786.44	1613.01	1857.83	4202.99
b) Purchases of stock-in-trade	-	-	-	-	-	-
c) Changes in inventories of fin. goods, stock-in-pro. & stock-in-trade	133.48	-114.80	-100.35	18.68	-166.60	52.94
d) Employee benefits expense	249.09	240.35	190.63	489.44	375.77	863.67
e) Finance costs	36.85	24.42	55.41	61.27	108.23	170.95
f) Depreciation and amortization expense	25.07	22.79	18.00	47.87	35.62	76.08
g) Other expenses						
Manufacturing & Operating (Stores and spares consumed, power & fuel, job work charges contract labour etc.)	84.51	96.82	81.10	181.33	160.40	325.47
Others	65.78	79.47	105.20	144.95	238.20	595.43
Total expenses	1441.02	1115.83	1136.43	2556.55	2609.45	6287.53
3. Profit/(Loss) before exceptional items and tax (1-2)	232.03	131.00	283.77	384.99	567.77	1128.03
4. Exceptional Items	-	-	211.53	-	211.53	211.53
5. Profit/ Loss(-) before tax (3+/-4)	232.03	131.00	72.23	384.99	356.25	916.51
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	303.37
Deffered tax	-	-	-	-	-	(10.36)
7. Profit/ Loss(-) for the period (5-/+6)	232.03	131.00	72.23	384.99	356.25	623.50
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	-	-	-	-	-
9. Total comprehensive income for the period (16+17)	232.03	131.00	72.23	384.99	356.25	623.50
10. Paid-up equity share capital (Face Value `10 Each)	2104.60	2104.60	2104.60	2104.60	2104.60	2104.60
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	7186.47
12. Debenture Redumption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items ` (not annualized)	1.10	0.62	0.34	1.83	1.69	2.96

Note: 1)

please be noted that Company has operated in a single segment viz. Drugs & Pharmaceuticals



Mahandem